Injectable PrEP: Adding choice to HIV prevention

  <p>An estimated 38,000 Americans are diagnosed with HIV annually. An important tool in the effort to end the ongoing epidemic is an injectable form of pre-exposure prophylaxis (PrEP), the first option to prevent HIV that does not involve taking a daily pill. The injectable form of the drug received FDA approval in late 2021 and has begun to hit the market. This is Part 2 of our conversation (Recorded May 16, 2022) with a panel of experts specializing in the HIV treatment and prevention. They discuss the benefits and what people at risk for HIV should know, challenges of implementation among providers and more. </p> <p>The panel includes: </p> <p><a href='https://www.northwell.edu/find-care/find-a-doctor/internal-medicine/dr-david-walter-rosenthal-do-phd-11317265'>David Rosenthal, DO, PhD</a>, medical director for the Center for Young Adult, Adolescent and Pediatric HIV.</p> <p><a href='https://www.cdc.gov/nchhstp/dear_colleague/2020/dcl-111720-dhap-director.html'>Demetre Daskalakis, MD</a>, director of the Division of HIV/AIDS Prevention (DHAP) for the Centers for Disease Control and Prevention (CDC)</p> <a href='https://www.hivcenternyc.org/charles-gonzalez'>Charles Gonzalez, MD</a>, medical director for the New York State Department of Health's AIDS Institute <p>More from the experts</p> <p>Dr. Rosenthal talks strengthening <a href='https://www.northwell.edu/news/the-latest/world-aids-day-2021-eliminate-disparities-and-the-virus-itself'>HIV prevention with PrEP</a> and expanding the four key strategies to end AIDS by 2030.</p>